It helps to identify

the most appropriate medication so that the patient can be stabilized as soon as possible
Drugs analyzed

Neuropharmagen analyzes the drugs for which sufficiently validated genetic information exists, and which enable drug response to be correlated with genetic variants. According to the U.S. Food and Drug Administration (FDA), pharmacogenetics can play an important role in identifying patients that respond and those that do not respond to certain medication, thereby avoiding adverse side effects and optimizing dosage.

The test currently can analyze 52 drugs, including all the neuropsychiatric medications with pharmacogenetic markers validated either FDA, the Clinical Pharmacogenetics Implementation Consortium (CPIC) or the Dutch Pharmacogenetics Working Group from the Royal Dutch Pharmacists Association (KNMP). The tool is being constantly updated as new scientific studies become available or new guidelines are issued.


ANTIDEPRESSANTS
Amitriptyline*
Bupropion
Citalopram
* Clomipramine*
Desipramine*
Desvenlafaxine
Doxepine
Duloxetine
Escitalopram
Fluvoxamine*
Fluoxetine
Imipramine*
Mianserine
Mirtazapine
Nortriptyline*
Paroxetine
Sertraline
Trimipramine*
Venlafaxine*
ANTIPSYCHOTICS
Aripiprazole*
Clozapine*
Haloperidol
Olanzapine*
Paliperidone
Perphenazine*
Pimozide
Quetiapine
Risperidone*
Thioridazine
Ziprasidone
Zuclopentixol
STABILIZERS AND ANTICONVULSANTS
Carbamazepine
Clobazam
Clonazepam
Lamotrigine
Levetiracetam
Lithium
Lorazepam
Oxcarbazepine
Phenobarbital
Phenytoin*
Pregabaline
Topiramate
Valproic Acid*
Vigabatrin
OTHERS
Amphetamines
Atomoxetine*
Methadone
Methylphenidate
Naloxone
Naltrexone
Pramipexol
(*) Drugs for which the FDA recommends genetic testing is carried out prior to being prescribed for the patient. List updated in February 2011.
www.fda.gov